Erasca (ERAS) Cash & Current Investments (2020 - 2026)
Erasca (ERAS) posted Cash & Current Investments of $243.8 million for Q1 2026, down 11.7% on a QoQ basis from $276.1 million in Q4 2025, and down 19.96% year-over-year from $304.6 million in Q1 2025.
Erasca (ERAS) Cash & Current Investments (2020 - 2026) Analysis & Trends
Erasca's Cash & Current Investments history runs 7 years deep, the most recent figure standing at $243.8 million for Q1 2026.
- Quarterly Cash & Current Investments fell 19.96% year-over-year to $243.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $243.8 million (down 19.96% YoY) and the FY2025 annual result came in at $276.1 million, down 7.45% from the prior year.
- Cash & Current Investments was $243.8 million for Q1 2026 at Erasca, down from $276.1 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $435.6 million in Q4 2022 and bottomed at $243.8 million in Q1 2026.
- A 5-year average of $330.9 million and a median of $312.3 million in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments surged 130.92% — and 2023, when it fell 28.3%.
- Erasca's Cash & Current Investments stood at $435.6 million in 2022, then declined by 28.3% to $312.3 million in 2023, then dropped by 4.5% to $298.3 million in 2024, then retreated by 7.45% to $276.1 million in 2025, then slipped by 11.7% to $243.8 million in 2026.
- Business Quant data shows ERAS's Cash & Current Investments at $243.8 million in Q1 2026, $276.1 million in Q4 2025, and $288.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Erasca | 5.81 Bn | 5.57 Bn | - | 243.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 243.79 Mn |
| Dec 31, 2025 | 276.08 Mn |
| Sep 30, 2025 | 288.40 Mn |
| Jun 30, 2025 | 300.66 Mn |
| Mar 31, 2025 | 304.59 Mn |
| Dec 31, 2024 | 298.31 Mn |
| Sep 30, 2024 | 318.91 Mn |
| Jun 30, 2024 | 408.41 Mn |
| Mar 31, 2024 | 393.76 Mn |
| Dec 31, 2023 | 312.35 Mn |
| Sep 30, 2023 | 296.67 Mn |
| Jun 30, 2023 | 317.25 Mn |
| Mar 31, 2023 | 389.74 Mn |
| Dec 31, 2022 | 435.62 Mn |
| Sep 30, 2022 | 355.93 Mn |
| Jun 30, 2022 | 292.73 Mn |
| Mar 31, 2022 | 392.53 Mn |
| Dec 31, 2021 | 414.48 Mn |
| Sep 30, 2021 | 486.65 Mn |
| Jun 30, 2021 | 193.67 Mn |